MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 6 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Superinvestors holding MLTX, Q2 2026
No superinvestor reported holding MLTX in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of MLTX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2024
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q1 2024
1 superinvestor holding at quarter end
- New
- Duquesne Family Office
- Sold out
- Soros Fund Management
Q4 2023
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+78.6%)
Q3 2023
1 superinvestor holding at quarter end